Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials

American Journal of Cardiology

Volumn 113, Issue 12, 2014, Pages 2018-2020

  Bangalore, Sripal ^a   Fayyad, Rana ^b   Hovingh, G Kees ^c   Laskey, Rachel ^b   Vogt, Liffert ^c   Demicco, David A ^b   Waters, David D ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; KIDNEY INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

ACUTE KIDNEY INJURY; AGED; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVALUATION STUDIES AS TOPIC; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84901618597     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.03.046     Document Type: Article

References (14)

1. C.R. Dormuth, B.R. Hemmelgarn, J.M. Paterson, M.T. James, G.F. Teare, C.B. Raymond, J.P. Lafrance, A. Levy, A.X. Garg, P. Ernst Canadian Network for Observational Drug Effect S Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases BMJ 346 2013 f880
2. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 (in press)
3. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, G. Ruf, E. Ritz, D. German, and I. Dialysis Study Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
4. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, J.A. Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels I High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
5. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
6. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller Investigators C Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
7. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, and N.K. Wenger Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
8. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points through Aggressive Lipid Lowering Study G High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
9. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin E, Infection Therapy-Thrombolysis in Myocardial Infarction I Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
10. A. Sarma The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome 2013 American Heart Association Scientific Sessions Dallas, TX
11. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, J.L. Rouleau, T.R. Pedersen, L.H. Gardner, R. Mukherjee, K.E. Ramsey, J. Palmisano, D.W. Bilheimer, M.A. Pfeffer, R.M. Califf, E. Braunwald Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
12. S.M. Brunelli, S.S. Waikar, B.T. Bateman, T.I. Chang, J. Lii, A.X. Garg, W.C. Winkelmayer, and N.K. Choudhry Preoperative statin use and postoperative acute kidney injury Am J Med 125 2012 1195 1204.e3
13. J.E. Ho, D.D. Waters, A. Kean, D.J. Wilson, D.A. Demicco, A. Breazna, C.C. Wun, P.C. Deedwania, K.K. Khush Investigators TNT Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study) Am J Cardiol 109 2012 1761 1766
14. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D.J. Wilson, A. Zuckerman, N.K. Wenger Investigators TNT Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 2008 1448 1454